Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts

Posted by Francis Steltz on Jun 15th, 2026

Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $25.4615.

KURA has been the subject of several recent research reports. Lake Street Capital initiated coverage on Kura Oncology in a report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target for the company. CLSA set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Wedbush cut their price target on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th.

Check Out Our Latest Analysis on Kura Oncology

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently added to or reduced their stakes in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares in the last quarter. Strs Ohio acquired a new position in Kura Oncology in the 1st quarter valued at approximately $143,000. Legal & General Group Plc raised its holdings in Kura Oncology by 35.1% in the 2nd quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after acquiring an additional 18,930 shares in the last quarter. Rhumbline Advisers raised its holdings in Kura Oncology by 13.0% in the 2nd quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after acquiring an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Kura Oncology by 244.5% in the 2nd quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after purchasing an additional 165,189 shares during the period.

Kura Oncology Price Performance

NASDAQ KURA opened at $9.05 on Monday. Kura Oncology has a twelve month low of $5.45 and a twelve month high of $12.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. The stock has a market capitalization of $803.37 million, a PE ratio of -2.70 and a beta of 0.36. The stock has a 50-day simple moving average of $9.31 and a 200 day simple moving average of $9.31.

Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The business had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Research analysts anticipate that Kura Oncology will post -3.47 EPS for the current year.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.